Promonitor

About the Product

The Promonitor family of tests measures both drug levels and anti-drug antibody levels with validated ELISA assays to complement biological therapies for drug monitoring.

Testing for drug bioavailability and immunogenicity includes IFX, Anti-IFX, ADL, Anti-ADL, RTX, Anti-RTX, ETN, Anti-ETN, GLM, Anti-GLM, VDZ, Anti-VDZ, UTK, and Anti-UTK. Personalize high-quality treatment of chronic inflammatory diseases with ease.

Promonitor-IFX: Internal evaluation studies have demonstrated that Promonitor IFX is able to quantify levels for the following biosimilars: CT-P13, SB2, GP1111

Promonitor-ANTI IFX: Internal evaluation studies have demonstrated that Promonitor anti-IFX is able to quantify anti-drug antibodies levels for following biosimilars: CT-P13, SB2

Promonitor-ADL: Internal evaluation studies have demonstrated that Promonitor ADL and Promonitor Anti-ADL are able to quantify the drug levels anti-drug antibodies levels for the following biosimilars: ABP501, SB5, GP 2017

Promonitor-RTX: Internal evaluation studies have demonstrated that the Promonitor RTX kit is able to quantify drug levels for the following biosimilars: CT-P10 (Truxima/Blitzima/Ritemvia/Rituzema)

Promonitor-ETN: Internal evaluation studies have demonstrated that the Promonitor ETN kit is able to quantify drug levels for the following biosimilars : SB4 (Benepali), GP2015 (Erelzi)

References: Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75(9):1693-1696. Fiorino G, Ruiz-Argüello MB, Maguregui A, et al. Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(3):601-606. Ruiz-Argüello MB, Maguregui A, Martinez A, Nagore D. P329 Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar. J Crohns Colitis. 2019;13(S1):S265-S266.

Key Features

• Optimized Therapy: Refine treatment of chronic inflammatory diseases with a individualized treatment for every patient enabling a personalized approach to therapy with biologics. Promonitor provides an early warning if the treatment regime may require modification.
• Cost Effective: Reduce the use of ineffective treatment strategies, allowing a more efficient use of available resources. Effectively manage resources with the information provided by Promonitor.
• Easy to use: Quickly generate easy to interpret results with ELISA-based tests and readily available equipment in 4 simple steps and 30 mins of hand-on time with precoated microplates and ready-to-use reagents.
• Flexible: Expand lab operations and workflow with multiple tests and configurations and test both drug levels and anti-drug antibody levels in manual or automated modes.
• High-quality: Results you can rely on with high specificity and sensitivity testing supported by a large number of peer-reviewed articles and referenced in over 100 publications.
• Monitoring Biosimilars: Evaluation studies have demonstrated that Promonitor kits are able to quantify not only biological drug levels, but also biosimilar drugs.